Cabbacis to Present at the Noble Emerging Growth Conference on October 8, 2025

Rhea-AI Impact

(Low)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

10/06/2025 - 08:15 AM

NIAGARA FALLS, N.Y.--(BUSINESS WIRE)-- Cabbacis (OTCQB: CABI), a U.S. federally-licensed tobacco-product manufacturer focused on harm-reduction products being developed under the iBlend™ brand name, today announced that management will attend the upcoming Noble Capital Markets October 2025 Emerging Growth Virtual Equity Conference, on October 8th and 9th 2025.

Joseph Pandolfino, CEO & Chairman of Cabbacis, is scheduled to present at the conference, as well as host one-on-one meetings with institutional investors throughout the event as follows:

Noble Conference Presentation
Date: Wednesday, October 8, 2025
Time: 3:30 p.m. Eastern Time
Format: Webcasted Presentation
Webcast: https://www.meetmax.com/sched/event_125441/investor_reg_new.html?attendee_role_id=NOBLE_INVESTOR

One-on-one Meetings
Date: Thursday, October 9, 2025

Joseph Pandolfino commented: "The Noble Capital Markets Investor Conference is an ideal venue for Cabbacis to share continued progress on our mission to advance tobacco-harm-reduction solutions. Building on highly positive clinical trial results for our patented iBlend™ cigarettes and the recent expansion of our global intellectual-property portfolio to 35 issued patents, we are preparing to file our first PMTA with the FDA around January 2026 while also exploring international licensing and partnership opportunities. We look forward to updating investors on our commercialization pathway for iBlend™ products that combine reduced-nicotine tobacco and hemp and our efforts to position Cabbacis as a leader in the next generation of harm-reduction alternatives."

Registration is required for conference participation. For more information or to schedule a meeting with management, please contact MZ Group at CABI@mzgroup.us.

About Cabbacis

Cabbacis (OTCQB: CABI) is focused on commercializing groundbreaking, patented harm-reduction tobacco products for the world’s one billion smokers. Led by its flagship iBlend™ reduced-nicotine cigarettes and vaporizer pods in development, the Company is well positioned ahead of the proposed FDA rule to cap the nicotine content in all U.S. cigarettes. iBlend™ predominately contains tobacco combined with non-intoxicating hemp to assist in smoking or vaping less, transitioning to less harmful tobacco products, and/or increasing quit attempts. The Company also plans to commercialize reduced-nicotine tobacco cigarettes and little cigars without hemp and vaporizer pods with conventional-nicotine tobacco and hemp.

In a recent clinical trial reported by the Company, Cabbacis cigarettes were highly rated for satisfaction and significantly reduced cravings for usual brand cigarettes. Cabbacis holds a global patent portfolio of 35 issued patents and various pending patent applications – primarily covering tobacco-hemp combinations in cigarettes and vaporizer pods – across key markets including the United States, Europe, China, India, Japan, Indonesia, Russia, South Korea, Canada, Australia, New Zealand, Mexico and Brazil – where approximately two-thirds of the world’s smokers collectively reside.

To learn more, please visit cabbacis.com or follow us on LinkedIn or X.

Cautionary Note Regarding Forward-Looking Statements

This press release includes forward-looking statements within the meaning of the federal securities law. All statements other than statements of historical or current facts made in this document are forward-looking. We identify forward-looking statements in this document by using words or phrases such as "anticipate," "believe," "consider," "continue," "could," "estimate," "expect," "foresee," "intend," "likely," "may," "objective," "potential," "plan," "predict," "project," "seek," "should," "will" and similar words or phrases and their negatives. Forward-looking statements reflect our current expectations and are inherently uncertain. Actual outcomes or results could differ materially for a variety of reasons. Factors that could cause actual results to differ materially are described in "Risk Factors" in our Regulation A Offering Circular qualified by the SEC on June 3, 2025 and in our Annual Report on Form 1-K for the period ended December 31, 2024 filed with the SEC. We undertake no responsibility to publicly update or revise any forward-looking statement except as required by applicable law.

This press release does not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of that state or jurisdiction.